not used title
not used title
PhRMA president and CEO Stephen J. Ubl spoke recently at The Hill’s event, “Pathways to Patient Affordability.” He spotlighted patients’ affordability challenges, the unintended consequences we’re already seeing from the government price setting provisions in the Inflation Reduction Act (IRA) and how policymakers can address harmful pharmacy benefit manager (PBM) practices.
On the IRA, Ubl noted that the legislation does “a poor job of balancing continued incentives for innovation without lower costs for patients at the pharmacy counter.”
He went on to note the law failed to address the role of other actors in the health care system, like insurance companies and pharmacy benefit managers (PBMs), that ultimately determine what patients pay out of pocket for medicines.
“Three PBMs now control 80% of the market and they’re vertically integrated with health plans,” Ubl said. “They do play a role in restraining costs but there is very little evidence the fruits of their efforts are actually translating into lower costs for consumers.”
To help lower costs for people at the pharmacy, the discussion touched on several policy ideas, including protecting copay assistance that many patients rely on, making sure no patient has to pay more for their medicine than their health plan pays and demanding more accountability from PBMs.
The main message? Let’s try to address the parts of the IRA that are already harming biopharmaceutical innovation and make sure patients are not paying more for their medicines than their health plans or PBMs. Or as Ubl commented, “The system is broken. We have a system today that’s set up for patient pushers at the expense of patients, and we need to fix it.
Learn more here: PhRMA.org/Middlemen
Emilie Signora
is a manager of public affairs at PhRMA focusing on the cost and value of medicines, as well as media executive visibility work. She previously worked for the U.S. Chamber of Commerce’s communications team. She received a B.A. in Communications from George Washington University. Outside of the office, Emilie enjoys traveling and spending time with her family.
Emilie Signora
New poll: 2 in 3 voters prefer a candidate committed to lowering health insurance premiums
September 18, 2026
Bayh-Dole: The fuel for America’s innovation engine
September 2, 2026
What AARP isn’t telling seniors about MFN
August 24, 2026
Policymakers should improve patient access and reject price controls
August 18, 2026
CMS proposal could discourage patient-centered innovation
August 18, 2026
ICYMI: Biopharmaceutical companies in America hit new investment milestone
August 14, 2026
Insurers blame GLP-1s for rising costs. The data tells a different story.
August 14, 2026
The FTC’s PBM enforcement actions gave us a glimpse behind the curtain; it’s time to let the light in.
August 7, 2026
Nearly 1 in 4 patients initially denied access to IRA medicines
August 6, 2026
Voters continue to voice their concerns on government price controls
July 24, 2026
Medicare Part D at 20: Building on a strong foundation
July 23, 2026
Message to USAging: Providers are raising concerns about coverage barriers
July 22, 2026
New PBM principles don't change the fundamental challenge: Access to lower-cost medicines
July 10, 2026
340B’s reality: A booming business for hospitals, pharmacies and corporate giants
June 25, 2026
Guest Blog: Price controls won’t lower costs when insurers control access
June 25, 2026
Insurers are blaming medicines for premium hikes in Massachusetts. The state's own data suggests otherwise.
June 24, 2026
World Sickle Cell Day: Recognizing the promise of gene therapy
June 19, 2026
MFN could disrupt the affordable medicines patients depend on
June 18, 2026
New “America Cures” ad: U.S. patients get new medicines first
June 15, 2026
Patients speak out: MFN won't address my affordability concerns
June 4, 2026
MFN price controls threaten American jobs and the U.S. economy
May 28, 2026
America's cancer research progress is real and worth protecting
May 28, 2026
Ahead of ASCO: Cancer innovation is promising, but policy choices matter
May 26, 2026
State price-setting boards create more questions than answers
May 20, 2026
New analysis highlights access to new medicines in the United States and abroad
May 13, 2026
MFN won’t lower costs when insurers call the shots
May 8, 2026
Guest Blog: How MFN price controls could decide my health care
April 30, 2026
Briefing: Capitol Hill panel on "Healthcare Denial Crisis in America"
April 24, 2026
MFN price controls would drain pensions and put retirements at risk
April 23, 2026
Survey confirms too many insured Americans face barriers to reliable health care
April 22, 2026
States should avoid repeating the IRA’s price‑setting mistakes
April 21, 2026
CMS undermines medical progress with MFN price controls
April 16, 2026
Trump Administration’s efforts to have other countries pay their fair share are underway
April 15, 2026
70% DENIED: How insurance denials are delaying and preventing care for millions of Americans
April 14, 2026
CMS’ MFN proposals won’t help seniors despite lofty promises
April 9, 2026
Voters voice concerns on government price controls
April 7, 2026
Virginia should be cautious about importing federal price-setting mechanisms
April 1, 2026
Policymakers shouldn’t double down on the IRA’s flaws with MFN
March 30, 2026
Hospitals drive nearly 80% of the U.S. health spending gap
March 25, 2026
How AI is transforming the drug innovation lifecycle
March 19, 2026
Insurers routinely block seniors’ access to medicines in Medicare Part D
March 18, 2026
MFN drug pricing risks reviving a harmful metric the U.S. rejected
March 16, 2026
Leadership in biopharmaceutical R&D provides U.S. patients the greatest access to innovative medicines
March 11, 2026
Harmful U.S. policies will help drive China’s global leadership in biopharmaceutical innovation
March 4, 2026
MFN undermines U.S. biopharmaceutical innovation
February 25, 2026
CMS puts patients and innovation at risk with MFN
February 24, 2026
No hassle, hidden markups or fees: AmericasMedicines.com
February 19, 2026
The Federal Trade Commission (FTC) takes important action to highlight and curb PBM abuses
February 17, 2026
Separating fact from fiction in the medicine supply chain
February 11, 2026
New list of selected drugs highlights growing consequences of government price setting
January 28, 2026
50-state poll says Americans are concerned that hospital markups hurt patients
January 27, 2026
Three things you should know from the insurer CEO congressional hearings
January 26, 2026
Price setting policies put cancer gains in jeopardy
January 16, 2026
Can’t get your medicine? Don’t count on your insurer.
January 15, 2026
Myth vs. Fact: How government price setting impacts innovation
November 24, 2025
The IRA’s price setting doesn’t guarantee lower costs or better access
November 17, 2025
Stop, collaborate and re-evaluate: ICER’s pricing report
November 14, 2025
California’s landmark PBM crackdown: A wake-up call for reform
November 13, 2025
Middlemen mark up drug prices and keep discounts meant for you
November 10, 2025
PhRMA calls on USTR to ensure foreign nations pay their fair share
November 4, 2025
Putting patients first: Breaking down barriers to care
October 28, 2025
Direct purchase programs can lower costs for patients
October 20, 2025
What seniors can expect this open enrollment
October 14, 2025
Part D premiums are going up, while choices are going down
October 8, 2025
PBMs say they want lower priced medicines, so why don’t they cover them?
October 7, 2025
Historic biopharmaceutical investments: A prescription for America’s future
September 29, 2025
Why states struggle to deliver savings: Middlemen and 340B siphon dollars from patients and states
September 15, 2025
PBMs are hiding hurdles to essential care
August 20, 2025
Celebrating 60 Years of Medicare
July 30, 2025
New study: PBMs and commercial insurers are quietly blocking prescription access
July 30, 2025
North Carolina puts patients first with rebate pass-through law
July 29, 2025
PBMs, not patents, are blocking access to lower-cost medicines
July 23, 2025
Medicare patients face higher drug costs, despite IRA promises
July 22, 2025
CMS continues to make a bad law worse
June 27, 2025
ICYMI: Forget Foreign Price Controls: There’s a better solution to lowering drug prices
June 26, 2025
What to know about vaccine ingredients: Aluminum and thimerosal
June 24, 2025
Americans are paying a 26% freerider tax on medicines because other countries don’t pay their fair share
June 17, 2025
Medicare Part D plans initially denied medicines for more than 70% of patients in four chronic disease areas
June 16, 2025
PhRMA Foundation celebrates 60 years of investing in future scientific leaders
June 11, 2025
New report: Post-approval innovation delivers substantial patient benefits
June 2, 2025
New “Balance the Scales” campaign highlights why Americans pay more for prescription medicines
May 21, 2025
How the 340B hospital markup program and PBMs drive up costs for U.S. patients
May 16, 2025
Foreign first pricing schemes don’t address why Americans pay more
May 15, 2025
The AHIP premium dollar corrected (again)
May 8, 2025
PBMs launch new ad campaign to block reforms
May 5, 2025
New analysis: Fewer treatments and cures under the IRA’s pill penalty
May 1, 2025
When middlemen own it all, patients pay the price
April 10, 2025
How the IRA is impacting the generic drug market
April 8, 2025
3 myths critics get wrong about intellectual property
March 28, 2025
New report finds more abuse of 340B program by hospitals and drug middlemen
March 24, 2025
Three reasons Congress should fix the IRA’s pill penalty
March 24, 2025
A closer look at how health care consolidation drives up patient costs, creates barriers to care
March 17, 2025
ICYMI: PhRMA submits comments to White House on artificial intelligence
March 17, 2025
Health care practitioners sound the alarm on middlemen-imposed barriers to patient care, need for policy change
March 13, 2025
Congress Keeps PBMs in the Hot Seat
March 6, 2025
4 things to know on Rare Disease Day
February 28, 2025
Improved treatments continue to lead to declining cancer mortality rates in the U.S.
February 25, 2025
Biopharmaceutical innovation for a healthier America: PhRMA releases new innovation report
February 21, 2025
New policy agenda charts solutions for a healthier America
February 20, 2025
A successful PhRMA Forum highlights our commitment to a healthier America
February 20, 2025
Guest Perspective: Prioritize Innovative Care
February 11, 2025
Preventing and fighting disease: A look at the biopharmaceutical progress made for patients in 2024
February 3, 2025
Virginia, Don't Let Politicians Take Away Your Medicine
January 23, 2025
Patients are losing as government price setting continues
January 17, 2025
Wrapping up the J.P. Morgan Healthcare Conference
January 16, 2025
FTC finds PBMs make billions in profit from marking up cancer, other critical generic drugs
January 14, 2025
PhRMA CEOs Tee Up Next Week's Health Care Conference
January 11, 2025
New study: Entities that don’t make medicines get half of what is spent on those medicines
January 7, 2025
A new administration poses new opportunities for patient access
December 17, 2024
Congratulations to our 2024 Working for Cures Employee Champions
December 11, 2024
Post-approval R&D is critical for fighting cancer. The IRA makes it more difficult.
November 13, 2024
Three things to know about 340B contract pharmacies
November 12, 2024
The PBM industry's desperate attempt to stop reform
November 12, 2024
PhRMA launches new ad calling for Congress to make sure savings go to patients, not PBMs
November 11, 2024
CMS needs to do better
November 4, 2024
ICYMI: Grounding policy reforms in real lived patient experiences is key to improving outcomes
October 31, 2024
New PES survey: Out-of-pocket costs lead key health care priorities ahead of the November election
October 30, 2024
Guest Post: My health care vote
October 29, 2024
Insurers continue shifting more costs on to patients
October 28, 2024
Americans speak out on health insurance barriers and need for policy change, according to the latest Patient Experience Survey
October 28, 2024
ICYMI: The powerful companies driving local drugstores out of business
October 25, 2024
Is CMS paying attention to the growing access barriers for Medicare patients under the IRA?
October 18, 2024
7 reasons why states shouldn’t copy the IRA’s price setting mistake
October 15, 2024
Did the administration consider the importance of blood cancer medicines to patients in price setting process?
October 8, 2024
Hispanic Heritage Month: Fighting for Hispanic patients
October 7, 2024
New Report: Tackling chronic conditions with preventive treatment
September 30, 2024
Did the administration consider the importance of blood clot medicines to patients in the price setting process?
September 25, 2024
PBMs and insurers off the hook: Sen. Sanders’ selective hearing on drug costs
September 24, 2024
Addressing the mounting threat of antimicrobial resistance
September 23, 2024
40 Years of Hatch-Waxman: What is the Hatch-Waxman Act?
September 19, 2024
Three ways state drug price setting boards fail patients
September 18, 2024
The Inflation Reduction Act could increase costs and reduce access for millions of seniors
September 17, 2024
Are the IRA’s Part B inflation rebates lowering costs for Medicare patients? No.
September 16, 2024
New research: American biopharmaceutical investment in R&D drives transformational innovation
September 16, 2024
Did the administration consider the importance of autoimmune disease medicines to patients in price setting process?
September 11, 2024
Key voter insights two months from Election Day
September 10, 2024
Patient priorities in the 2024 election
September 10, 2024
Did the administration consider the value of innovative diabetes medicines in price setting process?
August 28, 2024
How to protect your children’s health this school year
August 22, 2024
New survey: Insurers confirm IRA will reduce patient treatment options
August 20, 2024
The unintended consequences of government price setting in Medicare Part D
August 16, 2024
Don’t put the government between patients and their medicines
August 7, 2024
Biosimilars continue to drive market competition and increase savings for seniors
August 6, 2024
Industry-backed STEM programs have supported 111 million students and nearly 183,000 teachers
August 1, 2024
What is the low-income subsidy program and how is it changing?
July 31, 2024
Three things to know about the United Nations’ new HIV/AIDS report
July 31, 2024
Voters across all 50 states want state policymakers to focus on health insurance and PBM practices
July 30, 2024
Case study: How seniors could face access disruptions because of the IRA’s price setting provisions
July 22, 2024
WTAS: Voters voice concerns about PBM abuses, call on policymakers to act
July 19, 2024
PhRMA launches new ad in campaign exposing ways middlemen drive up costs
July 17, 2024
New Report: Vaccines continue to drive improved health outcomes
July 16, 2024
FTC report confirms PBMs profit at the expense of patients
July 10, 2024
New 50-state poll Americans want to hold health insurers and PBMs accountable for high out-of-pocket costs and other practices
July 9, 2024
The future of oncology R&D lies in policymakers’ hands
July 8, 2024
PhRMA reiterates concerns with IRA price setting program, urges CMS to mitigate harm
July 3, 2024
ICYMI: Hidden markups at mail-order pharmacies increase costs for employers
July 2, 2024
More than 60 researchers advocate on Capitol Hill
July 1, 2024
Showcasing the promise of biopharma at ASCO 2024
June 28, 2024
Alzheimer's & Brain Awareness Month: A conversation with Biogen
June 27, 2024
The IRA could lead to higher out-of-pocket costs for 3.5 million Medicare patients in 2026
June 25, 2024
Alzheimer's & Brain Awareness Month: A conversation with Eisai
June 24, 2024
ICYMI: What patients care about this election year
June 24, 2024
ICYMI: The Opaque Industry Secretly Inflating Prices for Prescription Drugs
June 21, 2024
Alzheimer's & Brain Awareness Month: A conversation with Eli Lilly and Company
June 20, 2024
ICYMI: Health care policy should be driven by patients, not politics
June 10, 2024
ICYMI: Misaligned policies undermine patient access
June 6, 2024
PhRMA Warns Federal Agencies: Consolidation and vertical integration among insurers, PBMs, and hospitals threaten patients
June 5, 2024
Women’s Health Month: A conversation with Astellas
May 31, 2024
ICYMI: Innovation transforms lives but misguided federal policies threaten patient outcomes
May 30, 2024
How the IRA is more coercive than any European government price setting scheme
May 29, 2024
Mental Health Awareness Month: Supporting loved ones and improving mental health in America
May 28, 2024
How government price setting fails to address systemic health care inequities
May 24, 2024
Women’s Health Month: A conversation with Sage
May 23, 2024
Ongoing federal probes shed light on PBM and insurer practices
May 20, 2024
The use of real-world data in drug development
May 13, 2024
Government price-setting boards: Why Minnesota needs to take a better approach
May 9, 2024
Critics repeat same, misleading narrative on potential “costs” of new medicines
May 7, 2024
WTAS: The consequences of consolidation and vertical integration
May 6, 2024
New analysis: Accelerated approval pathway is changing lives in underserved communities
April 30, 2024
IRA is already negatively impacting access to medicines in Part D
April 25, 2024
Insurance data: PBM reform has no material impact on premiums
April 24, 2024
Government price setting won’t help patients in Illinois
April 22, 2024
New study finds insurers and PBMs increasing access restrictions in Medicare Part D
April 16, 2024
New analysis: Flawed assessments of a medicine’s value jeopardize patient access
April 11, 2024
3 Takeaways from POLITICO’s Health Care Summit
April 3, 2024
World Vaccine Congress: Building on vaccine success
April 1, 2024
PBMs using 340B program to drive profits at patients’ expense
March 28, 2024
The impact of innovative medicines: A caregiver's perspective
March 26, 2024
ICYMI: More evidence of the IRA’s harmful consequences on post-approval research and development
March 25, 2024
Colorado is proof: Too many unanswered questions remain about state government price setting's impact on patients and providers
March 14, 2024
What new cures would mean to families
March 7, 2024
Watch: A conversation with Dr. Mike Ybarra on Rare Disease Day
February 29, 2024
American Heart Month: A nurse’s perspective
February 27, 2024
The truth about Nebraska's price setting push
February 13, 2024
Four years later, Maryland board still hasn’t delivered for patients
February 12, 2024
Proposed march-in framework would chill American innovation
February 7, 2024
Three things to know about antibody drug conjugates
February 2, 2024